press release from ceetox, peta and vito

2
4717 Campus Drive, Kalamazoo, MI 49008 269.353.5555 (P) 269.544.1077 (F) www.ceetox.com CeeTox Announces Positive Results of Ring Trial for PETA-Funded SenCeeTox ® Non-Animal Skin Allergy Assay For Immediate Release: CeeTox Contact: Ms. Jean Harden ([email protected]) +1-269-372-8711) PETA Contact: (U.K.) Dr. Gilly Stoddart ([email protected]; +44 (0)20 7837 6327) (U.S.) Dr. Amy Clippinger ([email protected]; 610-701-8605) August 9, 2013 Kalamazoo, Mich. --- CeeTox today reports the positive results of a recent phase of a PETA-funded validation study performed by the Flemish Institute for Technological Research (VITO)’s Applied BIO & Molecular Systems (ABS) team. The study confirms the ability of a second laboratory to perform CeeTox’s SenCeeTox ® skin sensitization assay to correctly classify chemicals as sensitizers or non-sensitizers. The SenCeeTox assay stands out from other non-animal assays – and even certain animal-based ones – in that it can categorize chemicals according to their potency. The results of the SenCeeTox trial conducted at VITO- ABS accurately predicted the ability to elicit a sensitization reaction for all 10 blinded compounds tested. Furthermore, it predicted the exact sensitization potency category for 9 out of the 10 compounds, classifying the 10 th compound by only a one potency category difference. CeeTox transferred the method for its SenCeeTox assay to VITO-ABS’s laboratory in Belgium as part of a blinded ring-trial funded by PETA U.K. Ring-trials are used to ensure that one laboratory’s results can be successfully replicated in other laboratories. This represents the first nongovernmental organization (NGO)- funded validation study of a non-animal method for regulatory use. After initial training, CeeTox provided VITO-ABS with a blinded set of 10 compounds. VITO-ABS tested the compounds in its lab and provided the data to CeeTox. The data were run through the proprietary CeeTox algorithm to predict an expected sensitization potency level, unblinded, and then compared to expected results. Because the results from the SenCeeTox assay have been so promising, further validation of this assay will be continued by Cosmetics Europe, after which all results will be submitted to the European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM). How SenCeeTox predicts sensitization Three dimensional, human, reconstructed epidermis (RHE) tissues are treated with multiple concentrations of each test article. This RHE skin model accurately replicates barrier properties, and possesses many of the key functional traits, signaling pathways and metabolic enzymes of normal human skin. After incubation, the skin tissues are then tested to assess the cytotoxic effect and reactivity of the test substances as well as gene expression of key genes along the Nrf2/Keap1/ARE signaling pathway, the activation of which leads to skin sensitization.

Upload: an-van-rompay

Post on 16-Jul-2015

137 views

Category:

Technology


6 download

TRANSCRIPT

Page 1: Press Release  from CeeTox, PETA and VITO

4717 Campus Drive, Kalamazoo, MI 49008 269.353.5555 (P) 269.544.1077 (F) www.ceetox.com

CeeTox Announces Positive Results of Ring Trial for PETA-Funded SenCeeTox® Non-Animal Skin Allergy Assay For Immediate Release:

CeeTox Contact: Ms. Jean Harden ([email protected]) +1-269-372-8711) PETA Contact: (U.K.) Dr. Gilly Stoddart ([email protected]; +44 (0)20 7837 6327) (U.S.) Dr. Amy Clippinger ([email protected]; 610-701-8605)

August 9, 2013

Kalamazoo, Mich. --- CeeTox today reports the positive results of a recent phase of a PETA-funded validation study performed by the Flemish Institute for Technological Research (VITO)’s Applied BIO & Molecular Systems (ABS) team. The study confirms the ability of a second laboratory to perform CeeTox’s SenCeeTox® skin sensitization assay to correctly classify chemicals as sensitizers or non-sensitizers. The SenCeeTox assay stands out from other non-animal assays – and even certain animal-based ones – in that it can categorize chemicals according to their potency. The results of the SenCeeTox trial conducted at VITO-ABS accurately predicted the ability to elicit a sensitization reaction for all 10 blinded compounds tested. Furthermore, it predicted the exact sensitization potency category for 9 out of the 10 compounds, classifying the 10th compound by only a one potency category difference. CeeTox transferred the method for its SenCeeTox assay to VITO-ABS’s laboratory in Belgium as part of a blinded ring-trial funded by PETA U.K. Ring-trials are used to ensure that one laboratory’s results can be successfully replicated in other laboratories. This represents the first nongovernmental organization (NGO)-funded validation study of a non-animal method for regulatory use. After initial training, CeeTox provided VITO-ABS with a blinded set of 10 compounds. VITO-ABS tested the compounds in its lab and provided the data to CeeTox. The data were run through the proprietary CeeTox algorithm to predict an expected sensitization potency level, unblinded, and then compared to expected results. Because the results from the SenCeeTox assay have been so promising, further validation of this assay will be continued by Cosmetics Europe, after which all results will be submitted to the European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM). How SenCeeTox predicts sensitization Three dimensional, human, reconstructed epidermis (RHE) tissues are treated with multiple concentrations of each test article. This RHE skin model accurately replicates barrier properties, and possesses many of the key functional traits, signaling pathways and metabolic enzymes of normal human skin. After incubation, the skin tissues are then tested to assess the cytotoxic effect and reactivity of the test substances as well as gene expression of key genes along the Nrf2/Keap1/ARE signaling pathway, the activation of which leads to skin sensitization.

Page 2: Press Release  from CeeTox, PETA and VITO

Page 2 of 2

Finally, the data are analyzed using a proprietary algorithm to predict the chemical’s likelihood of causing a human sensitization reaction. Importance of the test “This PETA-funded trial is an important step toward validating a reliably predictive full replacement non-animal test for regulatory use,” says Tim Mitchell, president of CeeTox, Inc. Jessica Sandler, director of PETA U.S.’s Regulatory Testing Division, says “We are excited to be the first animal rights organization involved in the validation of a non-animal test method and to move the science forward to save tens of thousands of mice and guinea pigs from painful skin sensitization testing.” Validation of this testing method is particularly timely in light of the ban on sales of cosmetics in Europe that have been tested on animals. Additionally, this test is important in light of the 2018 REACH deadline which will require a large number of chemicals to be tested for their ability to induce skin sensitization.

About CeeTox CeeTox, founded in 2003, is a contract research organization (CRO) focused on in vitro toxicity and safety screening of new products including cosmetics, personal care products, agricultural and household chemicals, and drug candidates. In vitro typically refers to a test that is performed in a cell model instead of in or on an animal. For more information, please visit www.ceetox.com. About PETA People for the Ethical Treatment of Animals (PETA) is an affiliate of PETA US, the largest animal rights organization in the world, which has more than three million members and supporters. PETA focuses its attention on the four areas in which the largest numbers of animals suffer the most intensely for the longest periods of time: on factory farms, in the clothing trade, in laboratories, and in the entertainment industry. For more information, please visit www.peta.org.uk. About VITO – team ABS VITO is an independent research and technology organization (RTO) providing innovative solutions to stimulate sustainable development. ABS offers (i) R&D: biological and molecular methods for human health diagnostics and biomonitoring (ii) Validation of alternative biological test methods and (iii) GLP/non-GLP contract testing. For more information, please visit www.vito.be.